
    
      The patients who need multi-vessel stenting with multi-vessel coronary artery disease will be
      enrolled.Each randomization of the enrolled subjects will be done 1:1 (biolimus A9-eluting
      stent : zotarolimus-eluting stent). Randomization will be stratified by two factors: Diabetes
      mellitus and Acute coronary syndrome.Clinical follow-up will occur at the following time
      points; 1 month, 1 year and 2 years.
    
  